A role for carbohydrates in immune evasion in AIDS

Nature Medicine

Volumn 4, Issue 6, 1998, Pages 679-684

  Reitter, Julie N ^a   Means, Robert E ^a   Desrosiers, Ronald C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS GLYCOPROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS MUTANT; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; BINDING SITES; CARBOHYDRATES; HIV ENVELOPE PROTEIN GP120; IMMUNIZATION; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; MUTATION; NEUTRALIZATION TESTS; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY, AMINO ACID; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VARIATION (GENETICS); VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

ANIMALIA; MACACA MULATTA; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0031749469     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0698-679     Document Type: Article

References (28)

1. Wei, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
2. Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
3. Koup, R.A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
4. Coffin, J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267, 483-489 (1995).
5. Pantaleo, G., Vaccarezza, M., Graziosi, C., Cohen, O.J. & Fauci, A. Antiviral immunity in HIV-1 infected long-term non-progressors (LTNPs). Semin. Virol. 7, 131-138 (1996).
6. Wolinski, S.M. et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272, 537-542 (1996).
7. Burns, D.P.W., Collignon, C. & Desrosiers, R.C. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J. Virol. 67, 4104-4113 (1993).
8. Chackerian, B., Rudensey, L.M. & Overbaugh, J. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus that evolve in the host alter recognition by neutralizing antibodies. J. Virol. 71, 7719-7727 (1997).
9. Borrow, P. et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med. 3, 205-211 (1997).
10. Goulder, P.J.R. et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Med. 3, 212 (1997).
11. Leonard, C.K. et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265, 10373-10382 (1990).
12. Back, N.K.T. et al. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199, 431-438 (1994).
13. Schonning, D., Jansson, B., Olofsson, S. & Hansen, J.-E.S. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1. J. Gen. Virol. 77, 753-758 (1996).
14. Bolmstedt, A. et al. Carbohydrate determinant NeuAc-Gal(1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120. J. Gen. Virol. 73, 3099-3105 (1992).
15. Schonning, K., Jansson, B., Olofsson, S., Nielsen, J.O. & Hansen, J.-E.S. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Virology 218, 134-140 (1996).
16. Bolmstedt, A. et al. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 12, 213-220 (1996).
17. Benjouad, A., Mabrouk, K., Gluckman, J.C. & Fenouillet, E. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein. FEBS Lett. 341, 244-250 (1994).
18. Fouts, T.R., Binley, J.M., Trkola, A., Robinson, J.E. & Moore, J.P. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71, 2779-2785 (1997).
19. Burton, D.R. A vaccine for HIV type 1: The antibody perspective. Proc. Natl. Acad. Sci. USA 94, 10018-10023 (1997).
20. Reitter, J.N. & Desrosiers, R.C. Attachment sites for N-linked carbohydrates in variable region 1 of envelope are dispensable for replication of simian immunodeficiency virus. J. Virol. (in the press).
21. Desrosiers, R.C. et al. Identification of highly attenuated mutants of simian immunodeficiency virus. J. Virol. 72, 1431-1437 (1998).
22. Burns, D.P.W. & Desrosiers, R.C. Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. J. Virol. 65, 1843-1854 (1991).
23. Means, R.E. & Desrosiers, R.C. Neutralization sensitivity of cell culture passaged simian immunodeficiency virus. J. Virol. 71, 7895-7902 (1997).
24. Wiley, D.C., Wilson, I.A. & Skehel, J.J. in Biological Macromolecules and Assemblies. Vol. 1 (ed. McPherson, A.) 299-336 (John Wiley & Sons, 1984).
25. Doe, B., Steimer, K.S. & Walker, C.M. Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans. Eur. J. Immunol. 24, 2369-2376 (1994).
26. Koff, W.C. The next steps toward a global AIDS vaccine. Science 266, 1335-1337 (1994).
27. Wyand, M.S., Manson, K.H., Garcia-Moll, M., Montefiori, D. & Desrosiers, R.C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70, 3724-3733 (1996).
28. Daniel, M.D. et al. Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. J. Gen. Virol. 68, 3183-3189 (1987).